Ebola hemorrhagic fever
diseaseOn this page
Also known as EbolaEbola feverEbola virus diseaseEbolavirus caused disease or disorderEbolavirus disease or disorderEbolavirus infectious diseaseEHF
Summary
Ebola hemorrhagic fever (MONDO:0005737) is a disease and 70 clinical trials. Top therapeutic interventions include amiodarone, vesicular stomatitis virus encoding ebola virus glycoprotein, and ansuvimab. A subtype of Filoviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 29
- Clinical trials: 70
Clinical features
Epidemiology
Prevalence records
3 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Cases/families | 28220 | Worldwide | Validated | |
| Annual incidence | <1 / 1 000 000 | Europe | Validated | |
| Point prevalence | <1 / 1 000 000 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
29 HPO clinical features (Orphanet curated; top 29 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001945 | Fever | Very frequent (80-99%) |
| HP:0002014 | Diarrhea | Very frequent (80-99%) |
| HP:0010702 | Increased circulating antibody level | Very frequent (80-99%) |
| HP:0020071 | Viremia | Very frequent (80-99%) |
| HP:0100749 | Chest pain | Very frequent (80-99%) |
| HP:0001882 | Leukopenia | Frequent (30-79%) |
| HP:0001888 | Lymphopenia | Frequent (30-79%) |
| HP:0001892 | Abnormal bleeding | Frequent (30-79%) |
| HP:0002013 | Vomiting | Frequent (30-79%) |
| HP:0002015 | Dysphagia | Frequent (30-79%) |
| HP:0002018 | Nausea | Frequent (30-79%) |
| HP:0002027 | Abdominal pain | Frequent (30-79%) |
| HP:0002239 | Gastrointestinal hemorrhage | Frequent (30-79%) |
| HP:0002249 | Melena | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0004396 | Poor appetite | Frequent (30-79%) |
| HP:0012115 | Hepatitis | Frequent (30-79%) |
| HP:0012735 | Cough | Frequent (30-79%) |
| HP:0025143 | Chills | Frequent (30-79%) |
| HP:0025439 | Pharyngitis | Frequent (30-79%) |
| HP:0040186 | Maculopapular exanthema | Frequent (30-79%) |
| HP:0100806 | Sepsis | Frequent (30-79%) |
| HP:0001254 | Lethargy | Occasional (5-29%) |
| HP:0001735 | Acute pancreatitis | Occasional (5-29%) |
| HP:0001873 | Thrombocytopenia | Occasional (5-29%) |
| HP:0002094 | Dyspnea | Occasional (5-29%) |
| HP:0002829 | Arthralgia | Occasional (5-29%) |
| HP:0005521 | Disseminated intravascular coagulation | Occasional (5-29%) |
| HP:0100247 | Recurrent singultus | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Ebola hemorrhagic fever |
| Mondo ID | MONDO:0005737 |
| EFO | EFO:0007243 |
| MeSH | D019142 |
| Orphanet | 319218 |
| DOID | DOID:4325 |
| ICD-10-CM | A98.4 |
| ICD-11 | 792755706 |
| NCIT | C36171 |
| SNOMED CT | 37109004 |
| UMLS | C0282687 |
| MedGen | 129219 |
| GARD | 0002035 |
| MedDRA | 10014071 |
| Is cancer (heuristic) | no |
Also known as: Ebola · Ebola fever · Ebola virus disease · Ebolavirus caused disease or disorder · Ebolavirus disease or disorder · Ebolavirus infectious disease · EHF
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Mononegavirales infectious disease › Filoviridae infectious disease › Ebola hemorrhagic fever
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
7 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| ADENOVIRUS TYPE 26 ENCODING EBOLA VIRUS GLYCOPROTEIN | Approved (phase 4) |
| Ansuvimab | Approved (phase 4) |
| Atoltivimab | Approved (phase 4) |
| Maftivimab | Approved (phase 4) |
| Odesivimab | Approved (phase 4) |
| Vaccinia Virus, Modified Encoding Ebola Virus Glycoprotein And Nucleoprotein | Approved (phase 4) |
| Vesicular Stomatitis Virus Encoding Ebola Virus Glycoprotein | Approved (phase 4) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Amiodarone, Brincidofovir, Favipiravir, Remdesivir, Sodium Chloride.
Clinical trials & evidence
Clinical trials
Clinical trials: 70.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 25 |
| Not specified | 17 |
| PHASE2 | 16 |
| PHASE3 | 6 |
| PHASE4 | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05992480 | PHASE4 | RECRUITING | REVIVE (Response to the Ebola Virus Vaccine) |
| NCT06587503 | PHASE4 | NOT_YET_RECRUITING | Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses |
| NCT03072030 | PHASE4 | COMPLETED | International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi |
| NCT06126822 | PHASE3 | RECRUITING | Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC |
| NCT06841614 | PHASE3 | NOT_YET_RECRUITING | EBOla Post-Exposure Prophylaxis |
| NCT02307591 | PHASE2/PHASE3 | WITHDRAWN | Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) |
| NCT02509494 | PHASE3 | COMPLETED | Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo |
| NCT03161366 | PHASE3 | COMPLETED | Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine |
| NCT04152486 | PHASE3 | UNKNOWN | Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC |
| NCT04228783 | PHASE3 | COMPLETED | A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants |
| NCT05202288 | PHASE2 | NOT_YET_RECRUITING | Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers |
| NCT06100913 | PHASE2 | ACTIVE_NOT_RECRUITING | Immunology of Ebola Vaccine |
| NCT02329054 | PHASE2 | COMPLETED | Efficacy of Favipiravir Against Ebola (JIKI) |
| NCT02380625 | PHASE1/PHASE2 | UNKNOWN | Multiple Treatments for Ebola Virus Disease (EVD) |
| NCT02662855 | PHASE2 | COMPLETED | Efficacy of Favipiravir Against Severe Ebola Virus Disease |
| NCT02818582 | PHASE2 | COMPLETED | GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen |
| NCT02876328 | PHASE2 | COMPLETED | Partnership for Research on Ebola VACcinations |
| NCT03031912 | PHASE2 | COMPLETED | African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola |
| NCT03929757 | PHASE2 | COMPLETED | A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants |
| NCT04028349 | PHASE2 | COMPLETED | ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo) |
| NCT04186000 | PHASE2 | COMPLETED | Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola |
| NCT04268966 | PHASE2 | WITHDRAWN | An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola |
| NCT04385719 | PHASE2 | COMPLETED | Drug-drug Interactions Between Remdesivir and Commonly Used Antiretroviral Therapy |
| NCT04711356 | PHASE2 | COMPLETED | Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study) |
| NCT04822376 | PHASE2 | UNKNOWN | Prophylaxis Vaccine Antibodies Ebola |
| NCT05064956 | PHASE2 | COMPLETED | Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) |
| NCT05130398 | PHASE1/PHASE2 | COMPLETED | Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon |
| NCT05284097 | PHASE2 | COMPLETED | Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study |
| NCT00374309 | PHASE1 | COMPLETED | Experimental Vaccine for Prevention of Ebola Virus Infection |
| NCT00605514 | PHASE1 | COMPLETED | Ebola and Marburg Virus Vaccines |
| NCT00646152 | PHASE1 | COMPLETED | Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study |
| NCT00997607 | PHASE1 | COMPLETED | Evaluating an Ebola and a Marburg Vaccine in Uganda |
| NCT01353027 | PHASE1 | COMPLETED | Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus |
| NCT01593072 | PHASE1 | WITHDRAWN | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers |
| NCT02240875 | PHASE1 | COMPLETED | A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo |
| NCT02267109 | PHASE1 | COMPLETED | Phase 1 Trial of Ebola Vaccine in Mali |
| NCT02295501 | PHASE1 | TERMINATED | A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease |
| NCT02296983 | PHASE1 | UNKNOWN | A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya. |
| NCT02326194 | PHASE1 | COMPLETED | A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. |
| NCT02368119 | PHASE1 | COMPLETED | Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| AMIODARONE | 4 | 3 |
| VESICULAR STOMATITIS VIRUS ENCODING EBOLA VIRUS GLYCOPROTEIN | 4 | 3 |
| ANSUVIMAB | 4 | 2 |
| FAVIPIRAVIR | 4 | 2 |
| REMDESIVIR | 4 | 2 |
| ATORVASTATIN | 4 | 1 |
| BRINCIDOFOVIR | 4 | 1 |
| IRBESARTAN | 4 | 1 |
| MATRIX-M1 ADJUVANT | 3 | 1 |
| HILTONOL | 2 | 1 |
| AVI-7537 | 1 | 1 |
| CHEMBL4061258 | 0 | 1 |
| CHEMBL5094495 | 0 | 1 |
| CHEMBL5280654 | 0 | 1 |
| CHEMBL5407656 | 0 | 1 |
| CHEMBL5430294 | 0 | 1 |
| CHEMBL5434013 | 0 | 1 |
| CHEMBL6143911 | 0 | 1 |